|Dr. Jan Schmidt-Brand||Chief Exec. Officer, Chief Financial Officer and Member of the Exec. Management Board||301.28k||N/A||1958|
|Prof. Andreas Pahl||Chief Scientific Officer, Head of R&D and Member of the Exec. Mgmt Board||210.68k||N/A||N/A|
|Sylvia Wimmer||Mang. of Corp. Communications||N/A||N/A||N/A|
Heidelberg Pharma AG, through its subsidiaries, operates as a biopharmaceutical company that focuses on oncology and antibodies, and specializes in antibody drug conjugates (ADCs) in Germany, Europe, the United States, China, and Australia. It is developing HDP-101, an antibody targeted amanitin conjugate (ATAC) candidate for the treatment of multiple myeloma; PSMA, an ATAC candidate to treat prostate cancer; CD19, an ATAC candidate for the treatment of haematological tumors; HuMAB 5B1, an ATAC candidate to treat metastatic pancreatic cancer; and NN, an ATAC candidate for treating leukemia. The company is also developing MESUPRON, an oral Urokinase-type plasminogen activator (uPA)/serine protease inhibitor to block the activity of tumor-relevant serine proteases, such as uPA, plasmin, and thrombin to prevent tumor growth and metastasis; REDECTANE, a diagnostic antibody for the treatment of clear cell renal cell carcinoma; and RENCAREX, a therapeutic antibody for the treatment of clear cell renal cell carcinoma. It also provides preclinical contract services. Heidelberg Pharma AG has strategic alliances with Bayer Corporation and Centocor Inc. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.
Heidelberg Pharma AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.